BioRexis is developing protein and peptide drugs with superior
half-life and pharmacokinetic profiles. The company’s
protein engineering technology uses a natural variant of the
human blood serum protein transferrin as a carrier protein and
as a scaffold for the effective delivery of proteins and peptides.
Cerionx (formerly Microplate Automation) has developed a new, patented technology and process that uses low temperature, atmospheric pressure plasma to clean and sterilize highly sensitive equipment, such as pharmaceutical and biotechnology laboratory equipment.
GlycoMimetics is capitalizing on recent advances in glycobiology
by developing small molecule drugs that mimic the actions of
carbohydrates. The company is focusing its initial efforts on
therapeutics to treat inflammatory diseases such as cystic fibrosis
and cancer.
HTH Worldwide is the leading provider of health insurance
to international students attending U.S. universities and an
innovator in online healthcare information, medical assistance
and insurance services for travelers around the globe.
Immune Control is an early-stage drug discovery company that
has developed novel approaches to immune modulation using small
molecule, serotonin antagonists.
Immunicon (IMMC, NASDAQ) has developed a revolutionary
diagnostic platform based on immuno-magnetic selection and
fluorescent characterization of rare cells in blood. The company’s
initial products diagnose and monitor cancer.
Ion Healthcare is introducing a new approach to identifying and managing patients suffering from obstructive sleep apnea (OSA). Ion utilizes a proprietary FDA approved portable sleep apnea diagnostic system and provides CPAP and disease management programs to OSA patients in the Mid-Atlantic.
Nucleonics has developed a proprietary method of RNA interference
to silence disease-causing genes. Initially, the company is
applying its technology to develop expressed interfering RNA
(eiRNA) therapies for the treatment of chronic Hepatitis B and
Hepatitis C viral infections.
Sensors for Medicine and Science has developed a portfolio
of patented and highly sensitive fluorescence molecular sensing
technologies. The company is commercializing two product suites:
a minimally invasive glucose monitor for diabetics and an oxygen
sensor to measure metabolic rate.
